Similarly, considering the hypothesised gut-brain spread of PD pathology in a subset of individuals, targeting TLR2/4 in the gut through lifestyle interventions, pre/probiotics or specific therapeutics could be very beneficial in early stages of the disease to alleviate α-synuclein aggregation and pathology. The gene discussed is TLR2; the disease is Parkinson disease.